BTAI icon

BioXcel Therapeutics
BTAI

Overview Fund Activity

96 hedge funds and large institutions have $325M invested in BioXcel Therapeutics in 2023 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 30 increasing their positions, 27 reducing their positions, and 10 closing their positions.

Holders
96
Holders Change
+13
Holders Change %
+15.66%
% of All Funds
1.54%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
23
Increased
30
Reduced
27
Closed
10
Calls
$5.8M
Puts
$3.67M
Net Calls
+$2.12M
Net Calls Change
+$264K

Top Buyers

1
State Street
1
State Street
Massachusetts
$32.9M
2
Wellington Management Group
2
Wellington Management Group
Massachusetts
$24.9M
3
Adage Capital Partners
3
Adage Capital Partners
Massachusetts
$38.8M
4
Bank of America
4
Bank of America
North Carolina
$6.36M
5
Two Sigma Investments
5
Two Sigma Investments
New York
$4.07M

Top Sellers

1
AIM
1
Artemis Investment Management
United Kingdom
$18.3M
2
BPA
2
Beacon Pointe Advisors
California
$0
3
Nuveen Asset Management
3
Nuveen Asset Management
Illinois
$1.15M
4
DCM
4
Driehaus Capital Management
Illinois
$7.25M
5
IC
5
Ikarian Capital
Texas
$2.48M
Name Holding Trade Value Shares
Change 		Shares
Change %
MFS
101
Mirabella Financial Services
United Kingdom
– -$349K -1,017 Closed
UBS AM
102
UBS AM
Illinois
– -$294K -857 Closed
HIS
103
Harvest Investment Services
Illinois
– -$218K -636 Closed
Rockefeller Capital Management
104
Rockefeller Capital Management
New York
– -$19K -56 Closed
CG
105
Cutler Group
California
– -$18K -54 Closed
WAM
106
Worth Asset Management
Texas
– -$4.3K -13 Closed
1 2 3 4
5